US 8921348
Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
granted A61KA61K31/56A61K31/567
Quick answer
US patent 8921348 (Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists) held by Corcept Therapeutics Incorporated expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/56, A61K31/567, A61K31/575, A61P